inVentiv Health Clinical, a global supplier of drug development services, announced that it has been selected for an osteoarthritis Investigational New Drug Application (IND) by IntelliCell BioSciences, Inc. IntelliCell is a regenerative medicine biotech that will be studying the use of adult autologous vascular cells from blood vessels in adipose tissue to treat osteoarthritis of the knee. IntelliCell's IND study will focus on proving the company's patented technology of Ultrasonic Cavitation as a method of producing stromal vascular fraction cells as a new approach and improvement on current treatment which in the worst cases can involve surgery. About 75% of people over 70 years of age show changes consistent with osteoarthritis and symptoms such as pain, joint stiffness and joint deformities. Osteoarthritis affects more than 25 million people in the United States alone.
inVentiv Clinical will work with the principal investigator to develop investigational clinical study protocols and will serve as the CRO on trials conducted at the Pensacola Center of the Andrews Institute in Gulf Breeze, Florida. According to inVentiv Health Clinical President Raymond Hill, the company has extensive therapeutic experience in general pain and osteoarthritis programs and a focus on partnering with innovative bioscience companies.
Read the full release here.